Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Dixy opened the first darkstore in Moscow

1/23/25 MGNT

MMK's sales in 2024 decreased by 10%

1/23/25 MAGN

MGKL expands the assortment matrix

1/22/25 MGKL

Mosenergo in 2024 increased electricity generation by 4.9%

1/22/25 MSNG

APRI sales in 2024 increased by 14.38%

1/22/25 APRI

Bank Saint-Petersburg” reported for 2024 by RAS

1/22/25 BSPB

Odnoklassniki launched a deiting service for the audience of 40+

1/22/25 VKCO

NKNH received the first tons of ethylene at the new EP-600 unit

1/21/25 NKNC

Solar Group acquires 49% of Gefest Technologies, a developer of SIEM platforms

1/21/25 RTKM

Pre-IPO Exalter applications will be accepted until February 19

1/21/25 OTCI